Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.
about
Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?Progress in the clinical detection of heterogeneity in breast cancerAdditional value of 18F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancerDetection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CTB-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis patients.Immuno-PET for Clinical Theranostic Approaches.Review: Receptor Targeted Nuclear Imaging of Breast Cancer.HER2-positive breast cancer is lost in translation: time for patient-centered research.Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling.Metastatic breast cancer: The Odyssey of personalization.Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician.Human Epidermal Growth Factor Receptor 2-Targeted PET/Single- Photon Emission Computed Tomography Imaging of Breast Cancer: Noninvasive Measurement of a Biomarker Integral to Tumor Treatment and Prognosis.Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine.[89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer.Immune Modulation Therapy and Imaging: Workshop Report.Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer.18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials.N-Acetylcysteine breaks resistance to trastuzumab caused by MUC4 overexpression in human HER2 positive BC-bearing nude mice monitored by 89Zr-Trastuzumab and 18F-FDG PET imagingDevelopment of Antibody-Drug Conjugates Using DDS and Molecular Imaging.89Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art 89Zr Radiochemistry.Multifunctional Desferrichrome Analogues as Versatile 89Zr(IV) Chelators for ImmunoPET Probe Development.ImmunoPET to help stratify patients for targeted therapies and to improve drug development.Improved Tumor Penetration and Single-Cell Targeting of Antibody Drug Conjugates Increases Anticancer Efficacy and Host Survival.Tumor Uptake of 64Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer.89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors.PET Radiometals for Antibody Labeling.Response of symptomatic brain metastases from HER-2 overexpressing breast cancer with T-DM1.Targeting HER2 in Nuclear Medicine for Imaging and Therapy.Evaluation of [89Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer.Cardiovascular Immunotherapy and the Role of Imaging.Pharmacokinetics, Biodistribution, and Radiation Dosimetry for 89Zr-Trastuzumab in Patients with Esophagogastric Cancer.Cancer: Imaging with antibodies.I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma.Molecular Imaging in Drug Discovery and Development.HER2 imaging in the ZEPHIR study.Polyethylene glycol-conjugated HER2-targeted peptides as a nuclear imaging probe for HER2-overexpressed gastric cancer detection in vivo.Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast CancerApplication of Immuno-PET in Antibody-Drug Conjugate DevelopmentNoninvasive assessment of characteristics of novel anti-HER2 antibodies by molecular imaging in a human gastric cancer xenograft-bearing mouse model
P2860
Q26744088-F47A3817-8CF4-47F4-98A0-87D2745D80A7Q28079224-22F68E8C-4354-4D3C-9B64-9FC7138B6F57Q33730822-3FFC8DFE-2AF0-48BD-9D3B-DB52B2DB0806Q37309906-11B9FF2B-72F4-44C3-B2B6-FC2B0B341344Q37424048-89B5CA4C-BE44-4027-A8B9-3919B051ED9AQ37631461-AB55FB84-C494-4E63-8056-60E116993FB0Q37690662-7ABA81D8-D5AF-4CD0-A29C-FB48BCED9E04Q38648765-A1B86E02-AAEB-44F4-8F74-AF3B23FF88BCQ38824661-A1AC2255-908D-42A4-8B74-3C0FFDBACC75Q38901163-F00B1B19-A75A-435C-8F34-C753FF4BE3EAQ39233197-510D05CF-716F-477B-B454-236EDFF20E85Q39346715-7E3F8C82-A7C4-44A3-94AB-B52DD8B2B696Q39389369-58DD69D4-C286-438A-9A48-97F96B28EE9CQ39794283-C578D14C-F49E-443E-B730-CA23EDB8B8DCQ40089191-7780FBF7-5F86-434B-BEC5-80704D3EAC9DQ40219495-3E529C24-5412-4CC7-8EDE-AA59A8BD38A1Q40409656-56E78189-97AF-42C9-AF7D-3D15D37892BFQ41347430-3F335D2B-4DB3-4E8A-A3B4-CA23007AEB9BQ41670098-278D139F-68FE-4D7A-A3E0-0CEF3063CEFEQ41690954-9898EFAC-B1EC-49AE-87FE-50A2787AB019Q41728421-A5A42EE5-8810-4415-953B-068742DA4252Q42388200-A5F630A1-6971-428D-B43E-DE883D8BD85FQ47271330-A8DC653B-61D2-42A9-9A87-197B878633BBQ47573583-3BE3DFAE-F917-45D6-A18B-6D4956E8D8C1Q48184539-830A6055-F6DB-49BA-8F88-8E77AA2C0CBBQ48228929-B4126F8E-2B3C-4A0B-80F1-88ADDCB05E63Q49049652-04EB3C15-4260-4EF4-89A1-B5C6C2CAA43FQ49700421-4B23C09C-A29E-4BA5-8CEF-91FEAEF7F74AQ50016491-7F025EED-EB33-4C3B-9033-102B66988EE7Q50085133-0707533D-806F-4BA4-9FC5-0E689FFB060FQ50571860-985F71F4-FF6F-451D-BAB1-FF543FFAFDF3Q51081078-B49EA1F2-980F-49E1-B21C-FAAE986206FCQ52672750-EBAEAB23-06A4-4E1C-9C7C-10047CBC92C2Q52694389-7D936958-7151-418D-825F-A338551D56CDQ55031732-DFFD4150-AD41-4B24-94FD-B9E169A06C2DQ55286461-0689463F-E1E2-438D-AA56-4B19D3B54FD5Q57110662-A1AC6469-0D6D-448A-91E9-9497B1AB3B08Q58132996-641863DB-238F-4C97-876F-AF868D0A34C9Q58743797-229B11B4-0A69-4909-92AC-E70BF5C24B04
P2860
Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Molecular imaging as a tool to ...... ine (T-DM1): the ZEPHIR trial.
@en
type
label
Molecular imaging as a tool to ...... ine (T-DM1): the ZEPHIR trial.
@en
prefLabel
Molecular imaging as a tool to ...... ine (T-DM1): the ZEPHIR trial.
@en
P2093
P2860
P50
P356
P1433
P1476
Molecular imaging as a tool to ...... sine (T-DM1): the ZEPHIR trial
@en
P2093
A H Brouwers
C P Schröder
L E Lamberts
O S Hoekstra
P2860
P304
P356
10.1093/ANNONC/MDV577
P577
2015-11-23T00:00:00Z